Clearside Biomedical, Inc. (CLSD)


-0.07 (-4.32%)
Symbol CLSD
Price $1.55
Beta 1.912
Volume Avg. 0.16M
Market Cap 93.233M
Shares () -
52 Week Range 1.26-7.73
1y Target Est -
DCF Unlevered CLSD DCF ->
DCF Levered CLSD LDCF ->
ROE 0.31% Neutral
ROA 0.23% Neutral
Operating Margin -
Debt / Equity 13.74% Neutral
P/E 155 Strong Buy
P/B 2.94 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest CLSD news

Dr. George Lasezkay
NASDAQ Global Market

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.